A Cure Rate Model with Discrete Frailty on Hodgkin Lymphoma Patients after Diagnosis
Archives of Advances in Biosciences,
Vol. 11 No. 4 (2020),
28 November 2020
,
Page 15-22
https://doi.org/10.22037/aab.v11i4.32576
Abstract
Introduction: Hodgkin lymphoma (HL) is an uncommon cancer of lymphocytes, characterized by cancerous Reed-Sternberg cells in an inflammatory background. HL is an exceptionally curable disease with combination chemotherapy, radiotherapy, or combined modality treatment. This analysis aimed to identify significant prognostic factors on the cure rate.
Materials and Methods: The medical records of 110 patients hospitalized from 2007 up to 2014 with 18 months follow-up was retrospectively reviewed in Taleghani hospital of Tehran, Iran. The survival time was set as the time interval between diagnosis and a patient's death from HL. Also, if the cure rate was present in survival, data encompasses zero frailty. Thus, using hyper-Poisson (hP) distribution as discrete frailty, the unobserved heterogeneity and random effects were accounted for.
Results: The estimated cure fraction was 81.2%, which was obtained after 2717 days (7.4 years). In noncured cases, the mean survival time was 1535 days (4.2 years). Also, the five and ten-year survival rates were 0.91 and 0.80, respectively. After diagnosis, results revealed that patients with age 45, hemoglobin 12, WBC 15000, and BMI 30 were associated with poor outcome by using simple analysis. More importantly, there is no significant difference between males and females in the cure of HL patients.
Conclusion: As expected, the study indicated that a high proportion of HL patients got cured. A cure rate model with discrete frailty utilization provided a suitable way to account for heterogeneity among HL patients.
- Cure rate models
- Survival analysis
- Hodgkin's lymphoma
- Discrete Frailty
How to Cite
References
Mathas S, Hartmann S, Küppers R. Hodgkin lymphoma: Pathology and biology. Seminars in hematology. 2016;53(3):139-47.
Surveillance Research Program NCI. Cancer Statistics. Seer. 2020.
Heron DE, Shogan JE, Mucenski JW. Innovations in chemotherapy and radiation therapy: Implications and opportunities for the Asia-Pacific Rim. Biomedical imaging and intervention journal. 2008;4(3):e40.
Rathore B, Kadin ME. Hodgkin's lymphoma therapy: past, present, and future. Expert Opin Pharmacother. 2010;11(17):2891-906.
Hochberg J, Waxman IM, Kelly KM, Morris E, Cairo MS. Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: state of the science. 2009;144(1):24-40.
Iran OWIRo. International Agency for Research On Cancer. 2018.
Shanbhag S, Ambinder RF. Hodgkin lymphoma: A review and update on recent progress. CA Cancer J Clin. 2018;68(2):116-32.
Bodis S, Kraus MD, Pinkus G, Silver B, Kadin ME, Canellos GP, et al. Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease. Journal of Clinical Oncology. 1997;15(9):3060-6.
Matasar MJ, Ford JS, Riedel ER, Salz T, Oeffinger KC, Straus DJ. Late morbidity and mortality in patients with Hodgkin's lymphoma treated during adulthood. J Natl Cancer Inst. 2015;107(4):djv018.
Gogtay NJ, Thatte UM. Survival Analysis. The Journal of the Association of Physicians of India. 2017;65(5):80-4.
Amico M, Keilegom IV. Cure Models in Survival Analysis. 2018;5(1):311-42.
Farewell VT. The use of mixture models for the analysis of survival data with long-term survivors. Biometrics. 1982;38(4):1041-6.
Price DL, Manatunga AK. Modelling survival data with a cured fraction using frailty models. 2001;20(9‐10):1515-27.
Bardwell GE, Crow EL. A Two-Parameter Family of Hyper-Poisson Distributions. Journal of the American Statistical Association. 1964;59(305):133-41.
Aalen OO, Tretli S. Analyzing incidence of testis cancer by means of a frailty model. Cancer causes & control : CCC. 1999;10(4):285-92.
Caroni C, Crowder M, Kimber A. Proportional hazards models with discrete frailty. Lifetime data analysis. 2010;16:374-84.
Balakrishnan N. Cure rate modelling. Statistical methods in medical research. 2017;26(5):1999.
Bröckelmann PJ, Eichenauer DA, Jakob T, Follmann M, Engert A, Skoetz N. Hodgkin Lymphoma in Adults. Dtsch Arztebl Int. 2018;115(31-32):535-40.
Iraj AK. Hodgkin's disease: assessment of treatment and survival rates in Iran. Asian Pacific journal of cancer prevention : APJCP. 2004;5(4):379-82.
Bouliotis G, Bessell EM. Hodgkin disease (1973–2002): long-term survival and cure fractions. Leukemia & Lymphoma. 2015;56(5):1278-85.
Moccia AA, Donaldson J, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, et al. International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: Altered Utility in the Modern Era. Journal of Clinical Oncology. 2012;30(27):3383-8.
Diefenbach CS, Li H, Hong F, Gordon LI, Fisher RI, Bartlett NL, et al. Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era. British journal of haematology. 2015;171(4):530-8.
Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. The New England journal of medicine. 1998;339(21):1506-14.
Shamloo N, Ghannadan A, Jafari M, Ahmadi S, Mortazavi H, Baharvand M. Head and Neck Lymphoma in an Iranian Population. Iran J Otorhinolaryngol. 2017;29(94):261-7.
Wagstaff J, Steward W, Jones M, Deakin D, Todd I, Wilkinson P, et al. Factors affecting remission and survival in patients with advanced hodgkin's disease treated with MVPP. 1986;4(2):135-47.
Straus DJ, Gaynor JJ, Myers J, Merke DP, Caravelli J, Chapman D, et al. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1990;8(7):1173-86.
Hohaus S, Massini G, Giachelia M, Vannata B, Bozzoli V, Cuccaro A, et al. Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010;28(15):2538-43.
Moghaddam Tabrizi F, Barjasteh S. Maternal Hemoglobin Levels during Pregnancy and their Association with Birth Weight of Neonates. Iranian journal of pediatric hematology and oncology. 2015;5(4):211-7.
Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet (London, England). 2008;371(9612):569-78.
Keegan TH, Glaser SL, Clarke CA, Dorfman RF, Mann RB, DiGiuseppe JA, et al. Body size, physical activity, and risk of Hodgkin's lymphoma in women. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2006;15(6):1095-101.
- Abstract Viewed: 140 times
- PDF Downloaded: 167 times